

Invesco Global Small & Mid Cap Growth Fund

Quarterly Performance Commentary

Mutual Fund Retail Share Classes
Data as of Sept. 30, 2019



Investment objective

The fund seeks long-term growth of capital.

Portfolio management

Steve Cao, Jason T. Holzer, Ryan A. Amerman, Borge Endresen

Fund facts

Nasdaq	A: AGAAX	C: AGACX
		Y: AGAYX
Total Net Assets	\$443,633,475	
Total Number of Holdings	78	

Top holdings	% of total net assets
DCC	5.31
MorphoSys	2.88
Deutsche Boerse	2.61
HomeServe	2.52
Onex	2.34
Fairfax Financial	2.05
IHS Markit	1.93
Hongkong Land	1.90
NCR	1.79
Nabtesco	1.79

Top contributors	% of total net assets
1. MorphoSys	2.88
2. Tupras Turkiye Petrol Rafinerileri	1.77
3. Ultra Electronics	1.71
4. KLA	1.17
5. Deutsche Boerse	2.61

Top detractors	% of total net assets
1. Micro Focus International	0.00
2. Hongkong Land	1.90
3. Fairfax Financial	2.05
4. Elanco Animal Health	0.00
5. Angel Yeast	1.06

Market overview

- + Weakening global economic data and ongoing US-China trade conflict contributed to higher market volatility in the third quarter. Data releases during the quarter showed slowing manufacturing activity and declining business investment, evidence that trade tensions were stifling economic growth across both developed and emerging markets.
- + Global recession concerns caused a sharp equity selloff in August as investors crowded into asset classes perceived to be safe havens, including US Treasuries and gold.
- + In September, both the Federal Reserve and European Central Bank cut interest rates, providing a measure of support for risk assets. Growing optimism about a potential trade deal also boosted equities in September.
- + However, except for the US and Japan, most regions declined during the quarter. Uncertainty about the UK's withdrawal from the European Union continued to weigh on UK and European equities, while political and trade issues affected areas of Latin America and Asia.

Positioning and outlook

- + The team initiated several new positions during the quarter including **Koito Manufacturing**, **SBM Offshore**, **Salesforce.com** and **Tourmaline Oil** (0.95%, 0.75%, 0.39% and 0.40% of total net assets, respectively). We sold several positions, including **Elanco Animal Health**, **Live Nation Entertainment**, **Autodesk** and **Bright Horizons Family Solutions** (all 0.00% of total net assets).
- + Since mid-June 2018, investors have generally shifted their focus away from richly valued momentum growth stocks toward fundamentals, valuation and risk. We hope the broadening in investor focus that has occurred since then will persist and develop into a more prolonged period of market rotation. In an environment where US growth might be peaking and volatility continuing, the team believes its quality growth style may be moving back into favor.
- + Regardless of the macroeconomic environment, the team remains focused on applying its well-established, long-term, bottom-up Earnings, Quality, Value (EQV) investment process that seeks to identify attractively valued, high-quality growth companies.

Performance highlights

- + Invesco Global Small & Mid Cap Growth Fund Class A shares at net asset value (NAV) had a positive return for the quarter and outperformed the MSCI All Country World Small Mid Growth Index. (Please see the investment results table on page 2 for fund and index performance).


Contributors to performance

- + At the sector level, fund holdings in the industrials and financials sectors outperformed those of the benchmark index and contributed to relative performance. Strong stock selection and an underweight in health care added to relative return as well.
- + Geographically, stock selection in the US, Germany and Turkey were among the largest contributors to relative return. An overweight in the rising Turkey market also added to relative results.
- + Germany-based biopharmaceutical company **MorphoSys** was the fund's largest contributor during the quarter. The company benefited from robust sales of its commercial product Tremfya and from good progress in its clinical development pipeline, notably with promising data for proprietary product Tafasitamab/MOR208.

Detractors from performance

- + Fund holdings in the real estate and consumer staples sectors underperformed the benchmark and negatively affected relative performance.
- + Lack of exposure to the utilities sector negatively affected relative return.
- + Geographically, the fund's holdings in Canada underperformed those of the benchmark index and detracted from relative return. An underweight in Japan and an overweight in China also detracted from relative performance.
- + Canada-based **Fairfax Financial** was among the largest detractors for the quarter. Despite solid underwriting results, the company posted underwhelming investment results, weighed down by the low interest rate environment and continued underperformance of value-oriented stocks. Despite these challenges, the team still finds **Fairfax** attractively priced as it is trading close to book value.

The fund's positioning versus the MSCI AC World Small Mid Growth Index (% underweight/overweight)



Investment results

Average annual total returns (%) as of Sept. 30, 2019

Period	Class A Shares		Class C Shares		Class Y Shares	Style-Specific Index
	Inception: 09/15/94	NAV	Inception: 08/04/97	NAV	Inception: 10/03/08	
	Max Load 5.50%		Max CDSC 1.00%			MSCI AC World Small Mid Growth Index
Inception	7.69	7.94	5.69	5.69	8.52	-
10 Years	7.38	7.99	7.18	7.18	8.26	9.57
5 Years	3.08	4.25	3.46	3.46	4.50	7.07
3 Years	4.63	6.63	5.81	5.81	6.87	8.48
1 Year	-2.72	2.97	1.27	2.16	3.19	-2.44
Quarter	-4.17	1.42	0.22	1.22	1.41	-1.56

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Visit invesco.com/performance for the most recent month-end performance. Performance figures reflect reinvested distributions and changes in net asset value (NAV). Investment return and principal value will vary, and you may have a gain or a loss when you sell shares. No contingent deferred sales charge (CDSC) will be imposed on redemptions of Class C shares following one year from the date shares were purchased. Performance shown at NAV does not include applicable CDSC or front-end sales charges, which would have reduced the performance. Class Y shares have no sales charge; therefore, performance is at NAV. Returns less than one year are cumulative; all others are annualized. Fund performance reflects any applicable fee waivers and/or expense reimbursements. Had the adviser not waived fees and/or reimbursed expenses currently or in the past, returns would have been lower. See current prospectus for more information. Index returns do not reflect any fees, expenses, or sales charges. Index source: FactSet Research Systems Inc.

Expense ratios	% net	% total	Asset mix (%)	
Class A Shares	1.36	1.37	Dom Common Stock	39.21
Class C Shares	2.11	2.12	Intl Common Stock	54.97
Class Y Shares	1.11	1.12	Cash	5.74
			Other	0.08

Per the current prospectus
Net = Total annual operating expenses less any contractual fee waivers and/or expense reimbursements by the adviser in effect through at least June 30, 2020. See current prospectus for more information.

For more information you can visit us at www.invesco.com/us

GDP is the monetary value of all the finished goods and services produced within a country's borders in a specific time period, though GDP is usually calculated on an annual basis. It includes all of private and public consumption, government outlays, investments and exports less imports that occur within a defined territory.

Class Y shares are available only to certain investors. See the prospectus for more information.

Asset allocation/diversification does not guarantee a profit or eliminate the risk of loss.

The fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

EQV stands for earnings, quality and valuation. Our investment process looks for companies with strong Earnings growth, they must be Quality companies that can sustain those earnings and these companies need to have attractive Valuations.

The S&P 500® Index is an unmanaged index considered representative of the US stock market. An investment cannot be made directly in an index.

The MSCI All Country (AC) World Small Mid Growth Index is a free float-adjusted market capitalization weighted index that is designed to measure small and mid-cap growth securities in developed and emerging markets. An investment cannot be made directly in an index.

About risk

Derivatives may be more volatile and less liquid than traditional investments and are subject to market, interest rate, credit, leverage, counterparty and management risks. An investment in a derivative could lose more than the cash amount invested.

The risks of investing in securities of foreign issuers, including emerging markets, can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

Growth stocks tend to be more sensitive to changes in their earnings and can be more volatile.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

The fund is subject to certain other risks. Please see the current prospectus for more information regarding the risks associated with an investment in the fund.

NOT FDIC INSURED | MAY LOSE VALUE | NO BANK GUARANTEE

Before investing, investors should carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund(s), investors should ask their advisors for a prospectus/summary prospectus or visit [invesco.com/fundprospectus](https://www.invesco.com/fundprospectus).

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Note: Not all products available at all firms. Advisors, please contact your home office.

The opinions expressed are those of the fund's portfolio management, are based on current market conditions and are subject to change without notice. These opinions may differ from those of other Invesco investment professionals. Holdings are subject to change and are not buy/sell recommendations.

All data provided by Invesco unless otherwise noted.